Morningstar Gives Illumina a BB+ Credit Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment research firm Morningstar has initiated a credit rating for Illumina of BB+, which it said reflects its negative view of the genetic analysis instrument business.

Morningstar said that although Illumina's financial position "looks solid," its rating "recognizes the fundamental advantages of competing in this industry." It also used Affymetrix's "recent downfall" in market position as a cautionary note for Illumina's creditors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.